SEARCH

SEARCH BY CITATION

References

  • 1.
    Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31:23692429.
  • 2.
    Hohnloser SH, Kuck KH, Lilienthal J, et al; for PIAF Investigators. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:17891794.
  • 3.
    Wyse DG, Waldo AL, DiMarco JP, et al; Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:18251833.
  • 4.
    Van Gelder IC, Hagens VE, Bosker HA, et al; for Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:18341840.
  • 5.
    Carlsson J, Miketic S, Windeler J, et al; for STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am CollCardiol. 2003;41:16901696.
  • 6.
    Opolski G, Torbicki A, Kosior DA, et al; for Investigators of the Polish HOT CAFÉ Trial. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFÉ) study. Chest. 2004;126:476486.
  • 7.
    Roy D, Talajic M, Nattel S, et al; Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358: 26672677.
  • 8.
    Martin-Doyle W, Essebag V, Zimetbaum P, et al. Trends in US hospitalization rates and rhythm control therapies following publication of the AFFIRM and RACE trials. J Cardiovasc Electrophysiol. 2011;22:548553.
  • 9.
    Ouyang F, Tilz R, Chun J, et al. Long-term results in catheter ablation in paroxysmal atrial fibrillation: lessons from a 5-year follow-up. Circulation. 2010;122:23682377.
  • 10.
    Bhargava M, Di Biase L, Mohanty P, et al. Impact of type of atrial fibrillation and repeat catheter ablation on long-term freedom from atrial fibrillation: results from a multicenter study. Heart Rhythm. 2009;6:14031412.
  • 11.
    Lafuente-Lafuente C, Mouly S, Longás-Tejero MA, et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomized controlled trials. Arch Intern Med. 2006;166:719728.
  • 12.
    Singh BN, Singh SN, Reda DJ, et al.; Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352: 18611872.
  • 13.
    Vorperian VR, Havighurst TC, Miller S, et al. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol. 1997;30: 791798.
  • 14.
    Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007;357:987999.
  • 15.
    Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation [published corrections appear in N Engl J Med. 2009;360:2487 and N Engl J Med. 2011;364:1481]. N Engl J Med. 2009;360: 668678.
  • 16.
    Page RL, Connolly SJ, Crijns HJ, et al. Rhythm- and rate-controlling effects of dronedarone in patients with atrial fibrillation (from the ATHENA trial). Am J Cardiol. 2011;107:10191022.
  • 17.
    Le Heuzey JY, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010;21:597605.
  • 18.
    Freemantle N, Lafuente-Lafuente C, Mitchell S, et al. Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone for the management of atrial fibrillation. Europace. 2011;13:329345.
  • 19.
    Wattigney WA, Mensah GA, Croft JB. Increasing trends for hospitalization for atrial fibrillation in the United States, 1989 through 1999: implications for primary prevention. Circulation. 2003;108: 711716.
  • 20.
    Wyse DG, Slee A, Epstein AE, et al. Alternative endpoints for mortality in studies of patients with atrial fibrillation: the AFFIRM study experience. Heart Rhythm. 2004;1:531537.
  • 21.
    Friberg L, Rosenqvist M. Cardiovascular hospitalization as a surrogate endpoint for mortality in studies on atrial fibrillation: report from the Stockholm Cohort Study of Atrial Fibrillation. Europace. 2011;13:626633.
  • 22.
    Køber L, Torp-Pedersen C, McMurray JJ, et al. Increased mortality after dronedarone therapy for severe heart failure [published correction appears in N Engl J Med. 2010;363:1384]. N Engl J Med. 2008; 358:26782687.